



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/830,071	04/23/2004	Kishore M. Gadde	1579-904	7687

23117 7590 09/23/2005

NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VA 22203

EXAMINER

JONES, DWAYNE C

ART UNIT PAPER NUMBER

1614

DATE MAILED: 09/23/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/830,071

Applicant(s)

GADDE ET AL.

Examiner

Dwayne C. Jones

Art Unit

1614

~ The MAILING DATE of this communication appears on the cover sheet with the correspondence address ~
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11JUL2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 10-12 and 18-43 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 10-12 and 18-43 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Status of Claims

1. Claims 10-12 and 18-43 are pending.
2. Claims 10-12 and 18-43 are rejected.

Information Disclosure Statement

3. The information disclosure statements filed on April 23, 2004 have been reviewed and considered, see enclosed copies of PTO FORM 1449.

Claim Rejections - 35 USC § 112

4. The rejection of claims 1-17 under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating obesity with the anticonvulsants of zonisamide and topiramate and the compound of bupropion which enhances the activity of norepinephrine and/or dopamine, does not reasonably provide enablement for other anticonvulsants as well as other compounds that are known functionally which enhance the activity of norepinephrine and/or dopamine is withdrawn in response to the amendment of July 11, 2005.

Claim Rejections - 35 USC § 102

5. The rejection of claims 1, 4-9, 11-24, and 35-41 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Coffin et al. of U.S. Patent Application No. US 2001/0025038 A1 is withdrawn.

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

8. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. The rejection of claims 1-9 and 11-17 under 35 U.S.C. 103(a) as being unpatentable over Ayala, R. or Shank of U.S. Patent No. 6,071,537 both in view of Gadde, K. et al. is withdrawn.

Art Unit: 1614

10. The rejection of claim 10 under 35 U.S.C. 103(a) as being unpatentable over Ayala, R. or Shank of U.S. Patent No. 6,071,537 both in view of Gadde, K. et al. is withdrawn.

11. Claims 10-12 and 18-43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ayala, R. in view of Shank of U.S. Patent No. 6,071,537 both in view of Anderson et al. of U.S. Patent No. 6,437,147. Ayala, R. teach of the administration of zonisamide is effective in decreasing weight loss in patients, (see abstract). Shank teaches of treating obesity with the administration of compounds of formula I, including topiramate, (see column 4 and claims 1-4). The prior art reference of Anderson. et al. specifically teaches of the administration of bupropion for the treatment of obesity, (see column 26, lines 47-49). "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. . . .[T]he idea of combining them flows logically from their having been individually taught in the prior art." *In re Kerkhoven*, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). For these reasons, the skilled artisan would have been motivated to combine these well-known pharmaceuticals for the treatment of the very same ailment of obesity. Moreover, the skilled artisan would have additionally been motivated to treat related ailments where the eating disorders are manifested, such as with bulimia nervosa or anorexia nervosa, due to the fact that eating disorders, for instance bulimia nervosa or anorexia nervosa, obviously may be treated with pharmaceutical agents that control or suppress the appetite of an individual in need thereof, which would assist the individual by inter alia

Art Unit: 1614

by controlling weight gain with these known compounds, such as zonisamide and topiramate. Accordingly, it would logically follow to reduce the risk of an individual from developing diabetes can be achieved by treating obesity as clearly taught by the prior art references of Ayala, R. or Shank of U.S. Patent No. 6,071,537 both in view of Anderson et al.

12. Claims 10-12 and 18-43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coffin et al. of US Patent Application Publication 2001/0025038.

13. It is first pointed out that the prior art reference of Coffin et al. is directed to a method for reducing cravings to food or an addictive substance with the administration of bupropion and zonisamide. This claim of Coffin et al. is written in the alternative, which does provide the skilled artisan with the necessary motivation and guidance to treat obesity or reduce weight gain in an individual in need thereof by reducing cravings for food to an individual in need thereof.

14. Accordingly, Coffin et al. teach of methods of reducing food cravings in mammals with the combined administration of antidepressant drugs, in particular bupropion, and anticonvulsant drugs, namely zonisamide, (see page 5 paragraphs 72, 76 and 78). In addition, Coffin et al. teach that these compounds may co-administered simultaneously or sequentially as well as being available in oral dosage forms, such as capsules and tablets, (see paragraph 84). Because the prior art reference of Coffin et al. teach of methods of reducing food cravings in mammals with the combined administration of antidepressant drugs, in particular bupropion, and anticonvulsant drugs, namely zonisamide, the prior art reference of Coffin et al. inherently teaches of the single

Art Unit: 1614

administration of zonisamide for the very same method of reducing food cravings in mammals. From these teachings, one having ordinary skill in the art is provided with the necessary teachings and motivation to employ zonisamide (see paragraphs 72, 76, and 78) and even specifically with bupropion (see claim 10) with Coffin et al.

Accordingly, it would logically follow to reduce the risk of an individual from developing diabetes can be achieved by treating obesity as clearly taught by Coffin et al.

Obviousness-type Double Patenting

15. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

16. The provisional rejection of claims 10-12 and 18-43 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 2-10, 13-19 of copending Application No. 10/440,404 is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant invention and copending Application No. 10/440,404 teach of treating obesity and hypertension (and diabetes or dyslipidaemia) with the administration of zonisamide

Art Unit: 1614

or topiramate along with bupropion. For these reasons, the skilled artisan would have been motivated to combine these well-known pharmaceuticals for the treatment of the very same ailment of obesity. Moreover, the skilled artisan would have additionally been motivated to treat related ailments where the eating disorders are manifested, such as with bulimia nervosa or anorexia nervosa, due to the fact that eating disorders, for instance bulimia nervosa or anorexia nervosa, obviously may be treated with pharmaceutical agents that control or suppress the appetite of an individual in need thereof, which would assist the individual by inter alia by controlling weight gain with these known compounds, such as zonisamide and topiramate.

17. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

18. The provisional rejection of claims 10-12 and 18-43 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 18-34 of copending Application No. 11/058,981 is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant invention and copending Application No. 11/058,981 teach of treating obesity and hypertension (and diabetes or dyslipidaemia) with the administration of zonisamide or topiramate along with bupropion. For these reasons, the skilled artisan would have been motivated to combine these well-known pharmaceuticals for the treatment of the very same ailment of obesity.

19. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Art Unit: 1614

20. The provisional rejection of claims 10-12 and 18-43 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 18-33 of copending Application No. 11/059,027. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant invention and copending Application No. 11/059,027 teach of treating obesity and hypertension (and diabetes or dyslipidaemia) with the administration of zonisamide or topiramate along with bupropion as well as its pharmacological metabolites. For these reasons, the skilled artisan would have been motivated to combine these well-known pharmaceuticals for the treatment of the very same ailment of obesity. Moreover, it is established that metabolites or pharmacological agents are inherent with the administration of the pharmacological agent.

21. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

22. The provisional rejection of claims 10-12 and 18-43 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 11/034,316. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant invention and copending Application No. 11/034,316 teach of treating weight gain with the administration of zonisamide or topiramate along with bupropion as well as its pharmacological metabolites. For these reasons, the skilled artisan would have been motivated to combine these well-known pharmaceuticals for the treatment of the very same ailment of obesity. Moreover, it is established that metabolites or

Art Unit: 1614

pharmacological agents are inherent with the administration of the pharmacological agent.

23. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (571) 272-0578. The examiner can normally be reached on Mondays, Tuesdays, Wednesdays, and Fridays from 8:30 am to 6:00 pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, may be reached at (571) 272-0951. The official fax No. for correspondence is (571)-273-8300.

Also, please note that U.S. patents and U.S. patent application publications are no longer supplied with Office actions. Accordingly, the cited U.S. patents and patent application publications are available for download via the Office's PAIR, see <http://pair-direct.uspto.gov>. As an alternate source, all U.S. patents and patent application publications are available on the USPTO web site (www.uspto.gov), from the Office of Public Records and from commercial sources.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Art Unit: 1614

Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see <http://pair-direct.uspto.gov> Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 1-866-217-9197 (toll free).


DWAYNE JONES
PRIMARY EXAMINER

Tech. Ctr. 1614
September 21, 2005